Paper Details

  1. Home
  2. Paper Details

AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis.

Author: BäumerWolfgang, EhingerAndreas M, GorrGilbert, HoppmannJoachim, KietzmannManfred, RundfeldtChris

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study tested the anti-inflammatory potential of AWD 12-281, a phosphodiesterase 4 inhibitor, in a model of allergic dermatitis in mice. Topically administered AWD 12-281 showed promising results in both prevention and treatment of the allergic reaction.
Paper Details　
Original Abstract of the Article :
AWD 12-281 (N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxoacetamide), a phosphodiesterase 4 inhibitor, which is optimized for topical administration, was tested in a model of allergic dermatitis in mice. To obtain an allergic dermatitis, BALB/c mice were sensitized...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1211/0022357021585

データ提供：米国国立医学図書館（NLM）

AWD 12-281: A Novel Phosphodiesterase 4 Inhibitor for Allergic Dermatitis

This research investigates the potential of AWD 12-281, a novel phosphodiesterase 4 inhibitor optimized for topical administration, as a treatment for allergic dermatitis. The study demonstrated the effectiveness of AWD 12-281 in preventing and treating inflammatory reactions in a mouse model of allergic dermatitis, suggesting its potential as a therapeutic agent for inflammatory skin conditions.

Promising New Approaches to Skin Inflammation Treatment

This study highlights the potential of AWD 12-281 as a novel therapeutic agent for allergic dermatitis. The findings suggest that topical administration of this phosphodiesterase 4 inhibitor could be an effective approach to managing inflammation and relieving symptoms in patients with allergic skin conditions. Further research and clinical trials are needed to confirm the safety and efficacy of this compound in humans.

A Potential Oasis for Itchy Skin: A New Approach to Dermatitis

Allergic dermatitis, like a persistent desert rash, can be uncomfortable and debilitating. This study offers hope for a new approach to managing this condition. AWD 12-281, like a refreshing oasis in the desert, shows promise for relieving the symptoms and controlling the inflammation associated with allergic dermatitis. The research highlights the potential of novel therapies for addressing this common and often challenging skin condition.

Dr. Camel's Conclusion

Allergic dermatitis, like an irritating desert sandstorm, can leave sufferers feeling itchy and uncomfortable. This research provides a glimmer of hope, showing the potential of AWD 12-281 to offer relief and control over the inflammation. Further research and clinical trials are needed to confirm its effectiveness, but this study paves the way for potential new treatments and a brighter future for those seeking relief from allergic dermatitis.
Date :
  1. Date Completed 2004-01-05
  2. Date Revised 2014-11-20
Further Info :

Pubmed ID

12956900

DOI: Digital Object Identifier

10.1211/0022357021585

Related Literature

Article Analysis
・Effects of diflorasone topical
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.